Posted by Michael Wonder on 18 Nov 2023
Halozyme announces argenx receives European Commission approval of Vvyvart SC with Enhanze for generalised myasthenia gravis
16 November 2023 - Vyvgart SC now approved for subcutaneous administration, adding to the already approved IV administration.
Halozyme Therapeutics today announced that argenx received European Commission approval of Vyvgart SC (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with Enhanze for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
